Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
LIPIDOR Aktie jetzt für 0€ handeln | |||||
02.06. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | 492 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
26.05. | Delisting of Lipidor AB from Nasdaq First North Growth Market | 215 | GlobeNewswire | On May 26, 2025, Lipidor AB was declared bankrupt by the Stockholm District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist... ► Artikel lesen | |
26.05. | XFRA L7R: AUSSETZUNG/SUSPENSION | 110 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIPIDOR AB L7R SE0012558617... ► Artikel lesen | |
26.05. | Suspension of Trading in Lipidor AB at FNSE | 163 | GlobeNewswire | 2025-05-26T06:33:44Z
Suspension
At Trading Venue FNSE
Due to Non Disclosure Of
Inside Information About The Issuer Or Financial Instrument
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent... ► Artikel lesen | |
25.05. | Lipidor AB: Lipidor applies for bankruptcy | 193 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 25th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's board has resolved to file for bankruptcy on behalf of the Company. The... ► Artikel lesen | |
24.05. | Lipidor AB: Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis | 106 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 24th May 2025 - (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study... ► Artikel lesen | |
19.05. | Lipidor AB: Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2 | 124 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 19th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached... ► Artikel lesen | |
17.03. | Lipidor AB: Lipidor announces all patients enrolled in ongoing Phase III study | 143 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 17th March 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been... ► Artikel lesen | |
28.02. | Lipidor AB: Lipidor AB (publ) publishes year-end report for 2024 | 216 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 28th February 2025 - Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available... ► Artikel lesen | |
21.01. | Lipidor AB: Lipidor announces half of patients enrolled in ongoing Phase III study | 514 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 21st January 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2... ► Artikel lesen | |
20.11.24 | Lipidor AB: Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025" | 154 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 20 November 2024 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business from CEO Ola Holmlund, also announcing a company presentation... ► Artikel lesen | |
28.08.24 | Lipidor AB: Lipidor AB (publ) publishes interim report for Q2 2024 | 143 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 28 August 2024 - Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January - June 2024. The report is available on the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ORAMED PHARMACEUTICALS | 1,841 | +1,13 % | ORAMED PHARMACEUTICALS INC. - 10-K/A, Annual Report | ||
MEDMEN ENTERPRISES | - | - | This Week In Cannabis: The MedMen Saga, Multi-Million-Dollar Financings, Controversies In LatAm And More | ||
OPUS GENETICS | 0,985 | +0,41 % | Opus Genetics, Inc.: Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited... ► Artikel lesen | |
BOIRON | 22,050 | -0,23 % | Boiron USA: Boiron's Camilia Tummy Receives Top Honors from Baby Innovation Awards | Newtown Square, Pennsylvania--(Newsfile Corp. - June 26, 2025) - Camilia Tummy® has received the "Baby Accessory Product of the Year" in the 2025 Baby Innovation Awards. Now in its fifth year, this... ► Artikel lesen | |
VERTICAL AEROSPACE | 5,950 | -1,65 % | Vertical Aerospace Completes World First Public Airport-to-Airport Flight | Completes first airport-to-airport flight by a full-scale, piloted winged tilt-rotor eVTOL designed for commercial service
VX4 prototype flew from Cotswold Airport to RAF Fairford ahead... ► Artikel lesen | |
PACIRA BIOSCIENCES | 19,000 | -2,56 % | Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of... ► Artikel lesen | |
RED LIGHT HOLLAND | 0,019 | 0,00 % | Red Light Holland Corp.: Red Light Holland Announces Bitcoin Balance Sheet Strategy and Names Scott Melker as Lead Cryptocurrency Advisor | Toronto, Ontario--(Newsfile Corp. - July 15, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the... ► Artikel lesen | |
INNOCARE PHARMA | 2,000 | +1,52 % | INNOCARE (09969): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL | ||
PHIBRO ANIMAL HEALTH | 25,000 | -1,57 % | Dividendenbekanntmachungen (04.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,75 EUR AGEAS SA/NV BE0974264930 - 2 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1934 EUR ANALOG... ► Artikel lesen | |
BAYER | 27,670 | -1,07 % | Aktien der Woche: BASF, Bayer, Deutsche Rohstoff / Almonty, Evotec, Rheinmetall, Renk | Sechs Aktien sorgten in dieser Woche für Schlagzeilen - mit Kurssprüngen, Analystenreaktionen oder überraschenden Unternehmensmeldungen. Die 4investors-Redaktion zeigt, welche Titel in den letzten Tagen... ► Artikel lesen | |
MERCK KGAA | 110,60 | -0,85 % | Verhaltene Kauflaune bei Merck KGaA-Aktie (112,35 €) | Wenig Kursbewegung derzeit bei dem Anteilsschein von Merck . Der jüngste Kurs betrug 112,35 Euro. Der Kurs der Aktie von Merck zeigt sich aktuell kaum verändert im Vergleich zu der letzten Notierung... ► Artikel lesen | |
NOVO NORDISK | 55,56 | +0,34 % | BERENBERG stuft NOVO NORDISK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Novo Nordisk mit einem Kursziel von 610 dänischen Kronen auf "Hold" belassen. Nach der ereignislosen ADA-Konferenz (American... ► Artikel lesen | |
GSK | 15,655 | -4,48 % | DEUTSCHE BANK RESEARCH stuft GSK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 1450 Pence auf "Hold" belassen. Ein mögliches "Revival" des Medikaments Blenrep gegen Knochenmarkkrebs... ► Artikel lesen | |
ROCKET LAB | 44,000 | -0,90 % | Neu: SpaceX bei Robinhood - Rocket Lab im Depot 2030 | Raumfahrt-Boom an der Börse. Visionen von Robotern auf dem Mars und neue Defense-Anwendungen sorgen für enormen Aufwind. SpaceX-Rivale Rocket Lab ist seit Kauf im Juni 2025 nun 55 Prozent im Depot 2030... ► Artikel lesen | |
MEI PHARMA | 5,920 | +31,56 % | MEI Pharma Stock Rises Over 32% |